SEC Form 4
Lycia Therapeutics, Inc. (LYCA) insider trading
No open-market LYCA insider purchases or sales were filed in the 12 months to Oct 27, 2026.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $0
- 0 filings
Who traded LYCA, and when
LYCA daily close from Oct 23, 2026 to Oct 27, 2026, between $26.73 and $30.00, last $26.73. No open-market insider purchases or sales were filed in this period.
No open-market insider purchases or sales were filed in the last 12 months.
Open-market trades
0 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| No open-market purchases or sales in the last 12 months. | ||||||
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
| No open-market purchases or sales in the last 12 months. | |||||||
GET /stocks/filings/vX/form-4?tickers=LYCA&filing_date.gte=2025-10-27&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"LYCA"
],
"issuer_cik": "0001806540",
"owner_cik": "0002050422",
"accession_number": "0002050422-26-000017",
"form_type": "4",
"filing_date": "2026-10-26",
"period_of_report": "2026-08-11",
"issuer_name": "Lycia Therapeutics, Inc.",
"issuer_trading_symbol": "LYCA",
"owner_name": "Bachrodt Amy",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": true,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "derivative",
"record_type": "transaction",
"security_title": "Stock Option (Right to Buy)",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-11",
"transaction_code": "A",
"equity_swap_involved": false,
"transaction_shares": 399746,
"transaction_price_per_share": 0,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 399746,
"transaction_value": 0,
"exercise_price": 3.7,
"expiration_date": "2036-08-10",
"underlying_security_title": "Common Stock",
"underlying_security_shares": 399746,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a)."
},
{
"id": "F2",
"description": "The options vest as to 1/4 of the total award on June 2, 2027, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date."
}
]
},
{
"tickers": [
"LYCA"
],
"issuer_cik": "0001806540",
"owner_cik": "0002159565",
"accession_number": "0002159565-26-000005",
"form_type": "4",
"filing_date": "2026-10-26",
"period_of_report": "2026-08-11",
"issuer_name": "Lycia Therapeutics, Inc.",
"issuer_trading_symbol": "LYCA",
"owner_name": "Staben Steven",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": true,
"is_other": false,
"officer_title": "Chief Scientific Officer",
"security_type": "derivative",
"record_type": "transaction",
"security_title": "Stock Option (Right to Buy)",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-11",
"transaction_code": "A",
"equity_swap_involved": false,
"transaction_shares": 110896,
"transaction_price_per_share": 0,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 110896,
"transaction_value": 0,
"exercise_price": 3.7,
"expiration_date": "2036-08-10",
"underlying_security_title": "Common Stock",
"underlying_security_shares": 110896,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a)."
},
{
"id": "F2",
"description": "The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Lycia Therapeutics, Inc.'s CEO sold stock?
No. Aetna Wun Trombley (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is LYCA’s insider data?
These are LYCA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track LYCA insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for LYCA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.